Woodstock Corp Grows Stock Holdings in Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

Woodstock Corp lifted its stake in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) by 7.8% during the fourth quarter, HoldingsChannel.com reports. The fund owned 194,919 shares of the biotechnology company’s stock after buying an additional 14,113 shares during the quarter. Woodstock Corp’s holdings in Aldeyra Therapeutics were worth $973,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of ALDX. Perceptive Advisors LLC grew its stake in Aldeyra Therapeutics by 7.9% in the second quarter. Perceptive Advisors LLC now owns 9,275,851 shares of the biotechnology company’s stock worth $30,703,000 after purchasing an additional 682,265 shares in the last quarter. Federated Hermes Inc. purchased a new stake in shares of Aldeyra Therapeutics in the 2nd quarter worth $1,758,000. Jacobs Levy Equity Management Inc. lifted its holdings in shares of Aldeyra Therapeutics by 163.4% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 476,949 shares of the biotechnology company’s stock worth $2,571,000 after buying an additional 295,864 shares during the period. International Assets Investment Management LLC grew its position in shares of Aldeyra Therapeutics by 397.0% during the 3rd quarter. International Assets Investment Management LLC now owns 287,287 shares of the biotechnology company’s stock worth $15,480,000 after buying an additional 229,487 shares in the last quarter. Finally, Barclays PLC increased its stake in shares of Aldeyra Therapeutics by 280.1% during the third quarter. Barclays PLC now owns 65,561 shares of the biotechnology company’s stock valued at $353,000 after buying an additional 48,313 shares during the period. 59.71% of the stock is owned by hedge funds and other institutional investors.

Aldeyra Therapeutics Price Performance

ALDX stock opened at $4.78 on Friday. Aldeyra Therapeutics, Inc has a 1-year low of $2.71 and a 1-year high of $6.55. The business has a 50-day moving average price of $4.95 and a 200 day moving average price of $4.95. The company has a debt-to-equity ratio of 0.18, a quick ratio of 6.80 and a current ratio of 6.80.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.25) EPS for the quarter, meeting the consensus estimate of ($0.25). As a group, equities research analysts anticipate that Aldeyra Therapeutics, Inc will post -0.92 earnings per share for the current fiscal year.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.